ld	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Reasons for Delay	Comments	Reasons for delay correspond to:
128500	17/LO:0025	223376	A Phase 3. Randonized. Double-Bind, Study Companies ABT-494 to Placebot in Placebot in Active Provisite Arthrifis Win Active Provisite Arthrifis Win Active Provisite Active Pro	No		0			09/11/2017	09/11/2017	0801/2018	09/11/2017	09/11/2017	Please Select	11/05/2018	D - Sponsor Delays		Sponsor
128501	17/YH/0055	215194	Multiple Interventions for Diabetic Foot Ulcer Treatment (MIDFUT) Trial	Yes	02/05/2018	25	64	89	14/09/2017	02/02/2018	24/05/2017	02/02/2018	27/02/2018	Please Select	27/02/2018	A - Permissions delayed/denied	Patients sought but no eligible patients identified	Neither
126502	17/SS/0082	222441	Start or STop Anticoagulants	Yes	09/07/2018	68	83	151	09/09/2016	08/02/2018	05/10/2017	06/03/2018	17/04/2018	Please Select	19/04/2018	A - Permissions delayed/denied	Delays in local review. Delay caused by sponsor in SIV and delayed confirmation from sponsor of study open to recruitment. Low target no eligible patients	Both
126503	17NS0018	223787	Female Urgency, Trial of Urdonyamics as Rousine Rousine Rousine Rousine Rousine Grund Rousine Grund Rousine Grund Rousine Grund Rousine Grund Rousine Grund Rousine Ro	Yes	31/07/2018	170	62	232	15/11/2017	11/12/2017	11/08/2017	27/02/2018	3005/2018	Please Select	31/05/2018	E - Staff availability issues	Delays in local review caused by staffing levels.	NNS Provider
126504	17/LO(0334	214459	FLO-ELA: FLuid Optimisation in Emergency LApardomy. Open multi-certre, mandomised controlled that of optimised multi-certre pushed hasmodynamic therapy compared to usual care in usual care in undergoing the optimised controlled to the optimised controlled to the optimised compared to usual care in undergoing optimised controlled to the	Yes	1005/2018	113	7	120	31/12/2017	1001/2018	2803/2017	01/05/2018	03/05/2018	Please Select	0405/2018	A - Permissions delayed/denied	Staff needed to be trained to be trained to the total to the total to the theatest TILLY to the theatest TILLY to the theatest TILLY to the theatest TILLY to the theatest TILLY to the theatest TILLY	NNS Provider
126505	17/SW/0127	225959	A multicentre randomised trial of first line treatment pathways for newly diagnosed immune thrombocytopeni a: Standard steroid treatment versus combined steroid and mycophenolate	No		108			03/03/2017	05/02/2018	03/07/2017	01/05/2018	24/05/2018	Please Select	24/05/2018	F - No patients seen	No eligible patients seen during the réported period	Neither
126506	17/EE/0497	238458	A double-billind, placebo- controlled, randomized trial to determine the safety and efficacy of EMA-01 100 mg bl.d. in reducing pain intensity as score in patients with painful diabetic neuropathy (EMPADINE)	Yes	1406/2018	57	42	99	19092017	07/03/2018	3001/2018	1303/2018	03/05/2018	Please Select	04/05/2018	A - Permissions delayed/denied	Local review delayed. National selection of the selection	Neither
126507	16/SW/0023	187812	Heimlich Valves In Secondary Spontaneous Pneumothorax: Enhancing Care (HI-SPEC)	No		27			20/09/2017	12/04/2018	22/08/2016	03/05/2018	09/05/2018	Please Select	10/05/2018	F - No patients seen	Low target, no eligible patients seen	Neither

126508	17/NW/0529	226070	The impact of postoperative Packing of Perianal Abscess Cavities: a multicentre randomised controlled trial	Na		126			23/08/2017	16/04/2018	06/12/2017	25/07/2018	20/08/2018	Please Select	26/10/2018	D - Sponsor Delays	Delays with sponsor assessment	Sponsor
126509	17/EE/0307	229942	A trial comparing the effect and safety of insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes.	No		29			18/01/2018	17/04/2018	21/09/2017	03/05/2018	16/05/2018	Please Select	17/05/2018	G - No patients consented	Eligible patients seen during the relevant period but did not consent to participate in the trial	Neither
126510	18/SW/0038	235662	Randomised controlled trial of the LoDED (Limit of Detection of Troponin and ECG Discharge) strategy versus usual care in adult chest pain patients attending the Emergency Department	Yes	05/07/2018	20	2	22	22/03/2018	13/06/2018	28/04/2018	21/06/2018	03/07/2018	Please Select	05/07/2018			Please Select
130145	18/SC/0243	240684	HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo- controlled trial assessing the effects of inclistran on clinical outcomes among people with atheroscierotic cardiovascular disease	No						06/08/2018	01/10/2018			Please Select		D - Sponsor Delays  E - Staff availability issues H - Contracting delays	HRA approval confirmation awaited. Contract negotiation delays. Staff required to run study	Both
130146	16/NW/0629	211995	The cystic fibrosis (CF) anti- staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of fluctoxicillin as a longterm prophylaxis agent for infants with CF.	No.		85			13/04/2018	09/07/2018	22/09/2016	21/09/2018	02/10/2018	Please Select		A - Permissions delayed/denied  D - Sponsor Delavs E - Staff availability issues		Both
130147	18/WM/0039	236159	A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadactinith (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14- 431 or M14-433	No		0			02/02/2018	02/02/2018	28/03/2018	02/02/2018	02/02/2018	Please Select		availability (south		Please Select
130148	18/WM/0037	228917	A Multicenter, Randomized, Double-Blind, Placebo- Controlled Induction Study of the Efficacy and Safety of Upadactifrib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease who have inadequately Responded to or are Intolerant to are Intolerant to Biologic Therapy	No		o			02/02/2018	02/02/2018	28/03/2018	02/02/2018	02/02/2018	Please Select	16/10/2018			Please Select
130149	16/SS/0070	202282	PREvention of Complications to Improve Outcome in elderly patients with acute Stroke. A randomised, open, phase III, clinical trial with blinded outcome assessment	Yes	05/10/2018	57	92	149	28/05/2017	09/05/2018	02/06/2017	22/06/2018	05/07/2018	Please Select	12/07/2018			Please Select
130150	18/LO/1192	248843	A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Na Yes Subjects with Moderately-to-Severely Active Crohn'7s Disease	No		0			21/08/2018	21/06/2018	24/08/2018	21/06/2018	21/06/2018	Please Select	16/10/2018			Please Select
130151	17/NW/0193	216411	IntAct: Intraoperative Fluorescence Angiography to Prevent Anastomotic Leak in Rectal Cancer Surgery	No		86			13/11/2017	25/06/2018	20/04/2017	28/09/2018	19/09/2018	Please Select	08/10/2018			Please Select
130152	17/SW/0019	220360	Cancer Surgery  A prospective observational cohort study examining the natural history of mesothelioma, exploring potential biomarkers and factors that may predict outcome, as well as providing a resource for future trials within a cohort. TILT Cohort study	No		20			30/06/2018	04/09/2018	16/03/2017	24/09/2018	24/09/2018	Please Select	27/09/2018			Please Select